ID: ALA3608986

Max Phase: Preclinical

Molecular Formula: C17H14N2OS

Molecular Weight: 294.38

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  Cc1ccccc1C(=O)c1cnc(Nc2ccccc2)s1

Standard InChI:  InChI=1S/C17H14N2OS/c1-12-7-5-6-10-14(12)16(20)15-11-18-17(21-15)19-13-8-3-2-4-9-13/h2-11H,1H3,(H,18,19)

Standard InChI Key:  ZFFONJXVKOIMJJ-UHFFFAOYSA-N

Associated Targets(Human)

MAP kinase p38 1586 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 294.38Molecular Weight (Monoisotopic): 294.0827AlogP: 4.43#Rotatable Bonds: 4
Polar Surface Area: 41.99Molecular Species: NEUTRALHBA: 4HBD: 1
#RO5 Violations: 0HBA (Lipinski): 3HBD (Lipinski): 1#RO5 Violations (Lipinski): 0
CX Acidic pKa: 12.59CX Basic pKa: 1.49CX LogP: 4.86CX LogD: 4.86
Aromatic Rings: 3Heavy Atoms: 21QED Weighted: 0.72Np Likeness Score: -1.59

References

1. Park H, Lee S, Hong S..  (2015)  Structure-based de novo design and synthesis of aminothiazole-based p38 MAP kinase inhibitors.,  25  (18): [PMID:26259807] [10.1016/j.bmcl.2015.07.094]

Source